Use of Thromboelastography Platelet Mapping for Assessment of Individual Platelet Response Secondary to Oral Antiplatelet Therapy after Percutaneous Coronary Intervention: An Attempt to Start Personalized Antiplatelet Therapy in India

Abstract High on-treatment platelet reactivity (HPR) with P2Y12 receptor antagonists in patients treated dual antiplatelet therapy (DAPT) is strongly associated adverse ischemic events after percutaneous coronary intervention (PCI). This prospective study was conducted to assess individual response and HPR medications post-PCI cases by thromboelastography mapping (TEG-PM). Total 82 who were on aspirin either clopidogrel, prasugrel, or ticagrelor evaluated. The percentage of inhibition arachidonic acid (AA) adenosine disdiphosphate (ADP) calculated [100-{(MA ADP/AA–MA Fibrin) / (MA Thrombin–MA × 100}], taking 50% as cut-off for HPR. clopidogrel prasugrel 14.29 12.5%, respectively. No detected ticagrelor. mean significantly higher 82.99, 95% confidence interval (CI) [77.3, 88.7] compared 72.21, CI [65.3, 79.1] 64.2, [52.5, 75.9] (p-value 0.041 0.003, respectively). Aspirin along a inhibition, lower the usage combined prasugrel. Additionally, it might also be concluded that TEG-PM could used effectively measure functions which would make oral more personalized cardiac patients.